Added to YB: 2026-09-15
Pitch date: 2026-09-12
SLN [neutral]
Silence Therapeutics plc
+0.85%
current return
Author Info
No bio for this author
Company Info
Silence Therapeutics plc, a biotechnology company, engages in the discovery and development of novel molecules incorporating short interfering ribonucleic acid (siRNA) to inhibit the expression of specific target genes in hematology, cardiovascular, and rare diseases.
Market Cap
$783.9M
Pitch Price
$12.95
Price Target
N/A
Dividend
N/A
EV/EBITDA
-11.30
P/E
-10.26
EV/Sales
1.2K
Sector
Biotechnology
Category
growth
Biotech Conference Coverage Day 4 Session 4 - Silence Therapeutics plc
SLN (quick overview): Silence Therapeutics offers a clean clinical-development setup in polycythemia vera and strong strategic fit with an established hematology company: validated biology, an approximately 88% Phase 2 response versus 19% on placebo and potential quarterly dosing versus weekly hepcidin-mimetic therapy. Management says its $200 million raise plus $72 million held at the end of Q2 provides 2.5–3 years of runway. The case depends on full ASH safety data, Phase 3 retaining a large placebo-adjusted effect and real patient and physician preference for quarterly dosing.
Read full article (2 min)